A leading manufacturer of adrenaline pens has issued a recall batches of pens due to a injection issue.
PharmaSwiss who produce Emerade pens which are used to treat a number of anaphlactic and allergic reactions.
It is believed the recall is being issued as the autoinjector is failing inject properly.
PharmaSwiss say the following batches are affected: Emerade 150mcg pre-filled pens, Emerade 300mcg pre-filled pens and Emerade 500mcg pre-filled pens are all affected.
The Health Products Regulatory Authority have urged anyone with the above pens to return them to their local pharmacy where they will be issued a replacement.